Prevalence and Transmission of Severe Acute Respiratory Syndrome Coronavirus Type 2 in Childcare Facilities: A Longitudinal Study

  1. Luise Haag
  2. Judith Blankenburg
  3. Manja Unrath
  4. Johanna Grabietz
  5. Elisabeth Kahre
  6. Lukas Galow
  7. Josephine Schneider
  8. Alexander H. Dalpke
  9. Christian Lück
  10. Leo Büttner
  11. Reinhard Berner
  12. Jakob P. Armann

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jpeds.2021.07.054
  2. ScreenIT

    SciScore for 10.1101/2021.04.16.21255616: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: After informed consent, 5 mL of peripheral venous blood were collected from adult participants and serological testing for IgG-antibodies against SARS-CoV-2 was conducted.
    IRB: Approval: The KitaCoviDD19-study which was approved by the Ethics Committee of the Technische Universität (TU) Dresden (BO-EK-180052020), registered on July 15th, 2020 and assigned the clinical trial number DRKS00022729.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Blood samples were assessed for SARS-CoV-2 IgG antibodies using a commercially available chemiluminescence immunoassay (CLIA) technology for the quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 (Diasorin LIAISON® SARS-CoV-2 S1/S2 IgG Assay).
    SARS-CoV-2 IgG
    suggested: None
    anti-S1
    suggested: None
    anti-S2 specific IgG
    suggested: None
    All samples with a positive or equivocal LIAISON® test result, as well as all samples from participants with a PCR-confirmed SARS-CoV-2 infection, were tested with two additional serological tests (chemiluminescent microparticle immunoassay (CMIA) intended for the qualitative detection of IgG antibodies to the nucleocapsid protein of SARS-CoV-2 (Abbott Diagnostics® ARCHITECT SARS-CoV-2 IgG) and an ELISA detecting IgG against the S1 domain of the SARS-CoV-2 spike protein (Euroimmun® Anti-SARS-CoV-2 ELISA)). Definitions: Participants with detectable antibodies in at least two assays were considered seropositive.
    SARS-CoV-2 spike protein (Euroimmun®
    suggested: None
    Anti-SARS-CoV-2
    suggested: None
    Software and Algorithms
    SentencesResources
    All samples with a positive or equivocal LIAISON® test result, as well as all samples from participants with a PCR-confirmed SARS-CoV-2 infection, were tested with two additional serological tests (chemiluminescent microparticle immunoassay (CMIA) intended for the qualitative detection of IgG antibodies to the nucleocapsid protein of SARS-CoV-2 (Abbott Diagnostics® ARCHITECT SARS-CoV-2 IgG) and an ELISA detecting IgG against the S1 domain of the SARS-CoV-2 spike protein (Euroimmun® Anti-SARS-CoV-2 ELISA)). Definitions: Participants with detectable antibodies in at least two assays were considered seropositive.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    Statistical Analysis: Analyses were performed using IBM SPSS 25.0 and Microsoft Excel 2010.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)
    Microsoft Excel
    suggested: (Microsoft Excel, RRID:SCR_016137)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are several limitations to our study. We enrolled a limited number of participants in our study, thus it was possible that infections remained undetected. Moreover, a lower sensitivity of PCR-testing for SARS-CoV-2 in stool samples than in oro- and nasopharyngeal swaps might also contribute to underestimating the true numbers of infections 14. However, the inclusion of low- as well as high-prevalence settings within the study period and the high participation rate of childcare workers in all facilities are strengths of our study. Additionally, the use of antibody testing instead of PCR testing reduces the possibility of missed undetected SARS-CoV-2 cases at least in parents and childcare workers.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.04.16.21255616v1 on medRxiv